Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Digital health tools

Reviewed as evidence on: Speech / language features and brain aging / dementia 4 studies (what the news said). Being listed means the study bears on the question, not that it agrees with the news.

Topic: Brain proteins, microglia and lab models

Butyrylcholinesterase inhibition offers one of the formulated solutions to tackle the aggravating symptoms of dementia that downgrades to cholinergic neuronal loss in Alzheimer’s disease. We developed a QSAR model to facilitate the identification of effective butyrylcholinesterase inhibitors. The model employs multi-feature selection and feature learning, improving the in silico screening efficiency and accelerating drug discovery efforts. This study aims to integrate Human Intestinal Absorption (HIA) values of butyrylcholinesterase (BChE) target inhibitors and their 50% inhibitory concentration (IC50) with machine learning tools. The model was developed using chemical descriptors in combination with supervised machine learning classification algorithms. Random Forest Classifier algorithm proved to be the ultimate best fit for classification model metrics including log loss probability (0.04225), accuracy score (98.88%) and Matthew’s correlation coefficient (0.98). Furthermore, a subset of the active dataset was used to study the regression based on HIA values using multi-feature selection and feature learning. The models were validated using precision, recall and F1 score for regression modelling. After integrating HIA data with existing machine learning algorithms, we observed a significant reduction of 89.63% in the number of inhibitors. The findings provide valuable pharmacological insights that can help in future design of drug development schemes different from conventional methods.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Dutta, S., Prabha, M., Kiran, R. S., & Ashoka, H. (2025). Enhanced in silico QSAR-based screening of butyrylcholinesterase inhibitors using multi-feature selection and machine learning. SAR and QSAR in environmental research. https://doi.org/10.1080/1062936x.2025.2466020

Vancouver

Dutta S, Prabha M, Kiran RS, Ashoka H. Enhanced in silico QSAR-based screening of butyrylcholinesterase inhibitors using multi-feature selection and machine learning. SAR and QSAR in environmental research. 2025. doi:10.1080/1062936x.2025.2466020. PMID: 39980415.

BibTeX

@article{dutta2025-39980415,
  author  = {Dutta, Sharmistha and Prabha, M. and Kiran, R.R. Siva and Ashoka, Hadagali},
  title   = {{Enhanced in silico QSAR-based screening of butyrylcholinesterase inhibitors using multi-feature selection and machine learning}},
  journal = {SAR and QSAR in environmental research},
  year    = {2025},
  doi     = {10.1080/1062936x.2025.2466020},
  pmid    = {39980415},
  url     = {https://doi.org/10.1080/1062936x.2025.2466020}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This in silico QSAR study developed a machine learning model to screen for butyrylcholinesterase inhibitors, finding a significant reduction of 89.63% in the number of inhibitors after integrating human intestinal absorption data. It is a computational drug-discovery screening step, not a tested treatment or cure.

Study details

How this study scored 34/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 2 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record left out, no data; Institution's track record 0 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 33 of the 96 points it could be judged on, which is 34 of 100. Total 34 of 100.33 of the 96 points we could judge = 34 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 33 of the 96 points we could judge it on, which is 34 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (SAR and QSAR in environmental research)
Journal's citation record 0 / 4 SAR and QSAR in environmental research: journal h-index 63 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 5 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.7 citations a year over 3 year(s) since 2025
Impact for its field and year 2 / 6 Cited 2.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 5 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Hadagali Ashoka holds only 8 work(s), too few to judge a track record — left out of this score
Institution's track record 0 / 3 Ramaiah Institute of Technology: institution h-index 122 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 39980415)
Free to read 0 / 2 Behind a paywall — scores zero
Points 33 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 33 of the 96 points we could judge it on is 34 out of 100.
Total 34 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Digital health tools

Also tagged “speech-language-markers-of-cognitive-decline”

4 studies in the library carry the topic tag “speech-language-markers-of-cognitive-decline”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 4 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Digital health tools

See all studies in Digital health tools →